|
[Briefing.com (PFE) Ticker Alert for In Play] 18-Jul-06 07:41 ET A Pfizer scientist sees research dividends ahead - NY Times (22.41) NY Times reports since Dr. John LaMattina became the research chief at the co in 2003, he has moved the co to invest heavily in drugs that raise so-called good cholesterol, betting that they will become the next major frontier in the treatment of heart disease. Now, as the co's first good-cholesterol-raising drug moves toward approval, the industry is scrambling to respond. He insists that the co - the entire industry, for that matter - is on the verge of a new age of drug discovery, one that will turn cancer, diabetes and other debilitating illnesses into manageable conditions. Decades of research into the mechanisms of disease have given drug makers hundreds of promising new cellular and genetic targets to study. As a result, the co has more potential drug compounds in early-stage development than ever before, Dr. LaMattina said. And in the last seven months, the co has introduced four new drugs, two of which are expected to be blockbusters, with peak yearly revs of $1 bln or more each. For now, the co's poor output has led analysts and industry critics to wonder whether its far-flung research operations, which encompass eight major campuses with 14,000 scientists on three continents, are simply too large to work efficiently. |
|
| aus der Diskussion: | Pfizer-Pharmawert total unterbewertet! 50% möglich! |
| Autor (Datum des Eintrages): | kfe1000 (18.07.06 14:09:24) |
| Beitrag: | 27 von 2,460 (ID:22696753) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |